EPIDUO FORTE GEL Rx
Generic Name and Formulations:
Adapalene 0.3%, benzoyl peroxide 2.5%; gel.
Galderma Laboratories, Inc.
Indications for EPIDUO FORTE GEL:
Treatment of acne vulgaris.
Apply thin film to affected areas of face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (eg, forehead, chin, cheek). Reduce frequency or discontinue if prolonged or severe irritation occurs.
Do not use on cuts, abrasions, eczematous or sunburned skin. Avoid eyes, lips, mucous membranes, sun, UV light. Increased irritation in extreme weather. Pregnancy (Cat.C). Nursing mothers.
Caution with other topical acne therapy (eg, peeling, desquamating, or abrasive agents). Avoid using concomitant topical irritants and waxing treated areas.
Retinoid + antibacterial/keratolytic.
Dry skin, contact dermatitis, skin irritation, eczema; local reactions (eg, erythema, scaling, dryness, burning, stinging), may bleach fabrics or hair.
Adapalene: biliary. Benzoyl peroxide: renal.
Gel—45g (tube or pump); Forte Gel—15g, 30g, 45g, 60g, 70g pump
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|